Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 8/20 | 0.64 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | PLAT | P00750 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31389779 | 0.83 | RIPK1 (0.47) | RIPK1GAATSHRGRM5PLAT | |
| SCHEMBL31389495 | 0.81 | RIPK1 (0.44) | RIPK1GAAMAPTKMT2A | |
| SCHEMBL20640756 | 0.78 | RIPK1 (1.00) | RIPK1TSHRGRM5KMT2A | |
| SCHEMBL20641141 | 0.78 | RIPK1 (1.00) | RIPK1TSHRGRM5KMT2A | |
| SCHEMBL20640677 | 0.78 | RIPK1 (1.00) | RIPK1TSHRGRM5KMT2A | |
| SCHEMBL29297718 | 0.74 | RIPK1 (0.55) | RIPK1 | |
| SCHEMBL6380228 | 0.73 | KMT2A (0.41) | RIPK1GAAALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL6379779 | 0.73 | RIPK1 (0.41) | RIPK1GAAALDH1A1HPGDPLAT | |
| SCHEMBL20645895 | 0.73 | RIPK1 (0.53) | RIPK1 | |
| SCHEMBL6380305 | 0.72 | NPC1 (0.43) | RIPK1ALDH1A1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975095-B2 | — | — | 2021-04-13 | — | — | US | disclosed |
| US-20190100530-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-04-04 | — | — | US | disclosed |
| WO-2019012063-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2019-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190100530-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | HSD17B7, CYP11B1, CYP11B2 | RIPK1 3489/4885GAA 1787/4885MAPT 2483/4885 |
| US-10975095-B2 | — | CYP1B1, UGT1A1, CYP4B1 | RIPK1 4628/4885GAA 961/4885MAPT 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.